Cognitive Decline in Non-demented PD

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
• Treatments: Atomoxetine Hydrochloride; Rivastigmine

Criteria

Inclusion Criteria:

• Clinical diagnosis of Parkinson's disease

• Respond to levodopa therapy

Exclusion Criteria:

• Dementia

• Psychiatric disorders including anxiety disorders, dissociative disorders, mood disorders, schizophrenia and related disorders, or ADD/ADHD

• Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver disease, kidney or renal failure or others that might require hospitalization

• Evidence for another neurological disease (history of seizures, Alzheimer disease, multiple sclerosis or other movement disorders);

• Currently using any of the study drugs;

• Colorblindness